Bayer AG BAYRY announced that the first patient has been enrolled in the late-stage SOHO-02 study on pipeline candidate BAY 292708. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) ...
Source LinkBayer AG BAYRY announced that the first patient has been enrolled in the late-stage SOHO-02 study on pipeline candidate BAY 292708. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) ...
Source Link
Comments